Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...